RedHill Biopharma acquires rights to anti-inflammatory molecule (RDHL)

RedHill Biopharma acquires rights to anti-inflammatory molecule (RDHL)

RedHill Biopharma (NASDAQ:RDHL) acquires exclusive worldwide development and commercialization rights to ABC294640, a Phase 1-stage anti-inflammatory small molecule under development at privately-held Apogee Biotechnology. Under the terms of …

(Visited 2 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.